About G protein-regulated inducer of neurite outgrowth 2
G protein-regulated inducer of neurite outgrowth 2 (GPRIN2) is a protein
from Homo sapiens identified by UniProt accession
O60269, 458 residues long.
MolForge cross-references it against 0 known binders and
27 disease associations.
Target properties
| Protein name | G protein-regulated inducer of neurite outgrowth 2 |
| UniProt accession | O60269 |
| Gene | GPRIN2 |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (27)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.28
- lung adenocarcinoma · score 0.04
- neoplasm · score 0.02
- COVID-19 · score 0.02
- colorectal cancer · score 0.01
- Intellectual disability · score 0.01
- hepatocellular carcinoma · score 0.00
- prostate carcinoma · score 0.00
- non-small cell lung carcinoma · score 0.00
- partial epilepsy · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60269-F1 | alphafold | PREDICTED | 50.54 | — |
Amino-acid sequence (458 residues)
MSSSRPEPGP WAPLSPRLQP LSQSSSSLLG EGREQRPELR KTASSTVWQA QLGEASTRPQ APEEEGNPPE SMKPARASGP KARPSAGGHW WSSTVGNVST MGGSDLCRLR APSAAAMQRS HSDLVRSTQM RGHSGARKAS LSCSALGSSP VHRAQLQPGG TSGQGGQAPA GLERDLAPED ETSNSAWMLG ASQLSVPPLD LGDTTAHSSS AQAEPKAAEQ LATTTCHALP PAALLCGMRE VRAGGCCHAL PATGILAFPK LVASVSESGL QAQHGVKIHC RLSGGLPGHS HCCAHLWGPA GLVPEPGSRT KDVWTMTSAN DLAPAEASPL SAQDAGVQAA PVAACKAVAT SPSLEAPAAL HVFPEVTLGS SLEEVPSPVR DVRWDAEGMT WEVYGAAVDL EVLGVAIQKH LEMQFEQLQR APASEDSLSV EGRRGPLRAV MQSLRRPSCC GCSGAAPE
Explore G protein-regulated inducer of neurite outgrowth 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets